First Case of Extremely Drug-resistant Tuberculosis in the U.S.

Public health officials have identified the first case of extremely drug resistant tuberculosis, or XXDR-TB, in the U.S., according to a recent report by the Associated Press.

Tuberculosis Late Diagnosis and Mortality Decrease among HIV Positive People in U.S.

The rate of death due to tuberculosis (TB) in the U.S. has decreased by half since the early 1990s, mostly attributable to a reduction among HIV positive people, according to a study described in the November 26, 2010 Morbidity and Mortality Weekly Report. What's more, among people with HIV, the proportion who were not diagnosed with TB until after they died also declined, reflecting better access to medical care.

Experimental Drug TMC207 Cuts Response Time for Multidrug-resistant Tuberculosis

Tibotec's investigational drug TMC207, added to a 5-drug combination regimen for 8 weeks, increased the cure rate for multidrug-resistant tuberculosis (MDR-TB) and reduced response time by more than half, according to study findings presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. A related report described good outcomes using meropenem/clavulanate in a small group of patients with extensively drug-resistant TB (XDR-TB).


More than 1 Million People Are Coinfected with HIV and Tuberculosis, WHO Report Says

The World Health Organization (WHO) last week issued a new report looking at the global status of tuberculosis (TB) and efforts to control the disease. The agency estimates that 9.4 million people became newly infected with TB in 2009, of whom 1.1 million were HIV positive. Although the TB death rate has fallen by one-third since 1990, there were still an estimated 1.7 million TB deaths -- or nearly 5000 per day -- in 2009. The continued spread of difficult-to-treat multidrug-resistance TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are growing concerns; XDR-TB has now been confirmed in 58 countries, according to the report.




CDC Awards $6.2 Million for Integration of HIV, Hepatitis, STD, and Tuberculosis Services

The U.S. Centers for Disease Control and Prevention (CDC) announced last week that it will award more than $6 million to fund demonstration projects to facilitate integration and collaboration among providers of prevention and care services for HIV, viral hepatitis, other sexually transmitted diseases (STDs), and tuberculosis. CDC will monitor and evaluate the projects to identify innovative approaches that can serve as models for other health departments.